Bacteriophage Encapsulation in Poly(Ethylene Glycol) Hydrogels Significantly Reduces Bacteria Numbers in an Implant-Associated Infection Model of Bone Repair


Christopher T. Johnson^{1,2}, Nina Dinjaski³, Maria Auxiliadora Prieto³, and Andrés J. García¹

1. Georgia Institute of Technology, Atlanta, GA; 2. Emory University, Atlanta, GA;

3. Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain

Statement of Purpose: Implant-associated infections account for over 1 million infections per year, typically leading to device failure and removal, causing significant patient morbidity. Bone fractures and non-union defects often require surgical intervention where biomaterials, bone grafting, or protein delivery (BMP-2) are used to repair the injury. In the US, nearly 112,000 orthopedic device infections occur annually¹. This motivates the development of dual functional materials capable of both healing bone and preventing infection.

Currently, few robust models are available to study how pathogenic bacteria interact with regenerative therapies. Our lab has recently developed a poly(ethylene glvcol) (PEG)-based hydrogel to deliver BMP-2 and integrin-specific peptides facilitating bone regeneration in a critical-sized radial segmental defect in a mouse,² which has been extended to evaluate antimicrobial properties. Bacteriophages are viruses specific to bacteria causing lysis. The phage infection amplifies and propagates through the pathogen, but is self-limited in that it cannot infect eukaryotic cells, and is cleared when the host bacteria is eliminated. This provides on-demand response to pathogens, while reducing the development of antibiotic resistance. The main objective of this study is to evaluate the feasibility and efficacy of bacteriophage presenting hydrogels in an infection model of bone repair. Methods: PEG hydrogel synthesis: PEG-maleimide hydrogels³ were reacted with the collagen mimetic peptide GFOGER and cross-linked with the protease degradable peptide VPM as outlined in Fig. 1.





Bacteriophage release from PEG hydrogels: Bacteriophage ϕ Paer14 was encapsulated in the PEG hydrogel and incubated in DPBS. Released bacteriophage was collected and measured at various time points using the soft agar overlay technique.

Bacteriophage effects on hMSC differentiation: Human mesenchymal stem cells (hMSC) were co-encapsulated with ϕ Paer14 and cultured in osteogenic media. Alkaline phosphatase (ALP) was measured after nine days.

Bacteriophage delivery to mouse radial segmental defect: A 2.5mm radial defect male C57/B6 mice was created and hydrogels containing BMP-2, Pseudomonas aeruginosa PsAer-9 pSEVAplaxA, and ϕ Paer4 were implanted in the defect (Fig. 3A). At 8 weeks, implants were recovered, degraded, and assayed for viable bacteria. **Results:** Encapsulated ϕ Paer14 is released linearly (R=0.96) from PEG hydrogels swelled in DPBS. Released phage is lytic against the PsAer-9 as determined by





Figure 2: A) Active ϕ Paer14 released from hydrogel, B) hMSC ALP expression after culture in osteogenic media in the presence of bacteriophage (**** = p < 0.001)



plaque formation (Fig. 2A). The presence of \oint Paer14 does not inhibit the differentiation potential of hMSCs encapsulated in PEG hydrogels cultured in osteogenic media as determined by ALP activity (Fig. 2B). BMP-2 loaded hydrogels containing no bacteria, PsAer-9, or PsAer-9 and \oint Paer4 were implanted into a mouse radial defect model (Fig. 3A). After 8 weeks, viable bacteria was recovered in all PsAer-9 groups demonstrating a well-defined, controlled infection model. Importantly, the \oint Paer4 treated hydrogels significantly reduced the number of viable bacteria recovered at 8 weeks after surgery, p < 0.05 (Fig. 3B).

Conclusions: We demonstrate bacteriophage can be encapsulated into PEG hydrogels without inhibiting bactericidal ability. The presence of bacteriophage does not alter the differentiation potential of hMSCs suggesting they do not disrupt bone formation. Bacteriophage delivery significantly reduces viable bacteria in a chronic implant infection model, providing proof of concept for their feasibility as an antimicrobial strategy. Further investigation is required to assess the biocompatibility of bacteriophage, as well as the immune response and effects on bone formation of bacteriophage delivery.

References: 1. Nair, MB; Curr opin Biotechnol. 2013, 22, 721-725; 2. Shekaran, A; Biomaterials. 2014, 35, 5453-5461; 3. Phelps, EA; Adv Mater. 2012, 24, 64-70.

Acknowledgements: Funding provided by S2013/MIT-2807 (MAP) and NIH grants R01 AR062368 and R01 AR062920 (AJG). We thank Rodney Donlan for bacteria and bacteriaphage samples and V. de Lorenz for plasmids.